These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37770762)

  • 1. Validity, diagnostics and feasibility of the Italian version of the Montreal Cognitive Assessment (MoCA) in Huntington's disease.
    Aiello EN; Solca F; Torre S; Lafronza A; Maranzano A; Bonetti R; Scheveger F; Maffi S; Ceccarelli C; Scocchia M; Casella M; Verde F; Migliore S; Silani V; Ticozzi N; Squitieri F; Ciammola A; Poletti B
    Neurol Sci; 2024 Mar; 45(3):1079-1086. PubMed ID: 37770762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive Screening Tests in Huntington Gene Mutation Carriers: Examining the Validity of the Mini-Mental State Examination and the Montreal Cognitive Assessment.
    Ringkøbing SP; Larsen IU; Jørgensen K; Vinther-Jensen T; Vogel A
    J Huntingtons Dis; 2020; 9(1):59-68. PubMed ID: 31658065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity and diagnostics of the Italian version of the Montreal Cognitive Assessment (MoCA) in non-demented Parkinson's disease patients.
    D'Iorio A; Aiello EN; Amboni M; Vitale C; Verde F; Silani V; Ticozzi N; Ciammola A; Poletti B; Santangelo G
    Aging Clin Exp Res; 2023 Oct; 35(10):2157-2163. PubMed ID: 37480503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinimetrics and feasibility of the Italian version of the Frontal Assessment Battery (FAB) in non-demented Parkinson's disease patients.
    Aiello EN; D'Iorio A; Solca F; Torre S; Bonetti R; Scheveger F; Colombo E; Maranzano A; Maderna L; Morelli C; Doretti A; Amboni M; Vitale C; Verde F; Ferrucci R; Barbieri S; Zirone E; Priori A; Pravettoni G; Santangelo G; Silani V; Ticozzi N; Ciammola A; Poletti B
    J Neural Transm (Vienna); 2023 May; 130(5):687-696. PubMed ID: 36976351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinimetrics of the Italian version of the Montreal Cognitive Assessment (MoCA) in adult-onset idiopathic focal dystonia.
    D'Iorio A; Aiello EN; Trinchillo A; Silani V; Ticozzi N; Ciammola A; Poletti B; Esposito M; Santangelo G
    J Neural Transm (Vienna); 2023 Dec; 130(12):1571-1578. PubMed ID: 37308662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Montreal cognitive assessment for evaluating cognitive impairment in Huntington's disease: a systematic review.
    Rosca EC; Simu M
    CNS Spectr; 2022 Feb; 27(1):27-45. PubMed ID: 33023702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic properties of the Frontal Assessment Battery (FAB) in Huntington's disease.
    Solca F; Aiello EN; Migliore S; Torre S; Carelli L; Ferrucci R; Priori A; Verde F; Ticozzi N; Maffi S; Ceccarelli C; Squitieri F; Silani V; Ciammola A; Poletti B
    Front Psychol; 2022; 13():1031871. PubMed ID: 36533005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of the Parkinson's disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington's disease.
    Martinez-Horta S; Horta-Barba A; Perez-Perez J; Sampedro F; de Lucia N; De Michele G; Kehrer S; Priller J; Migliore S; Squitieri F; Castaldo A; Mariotti C; Mañanes V; Lopez-Sendon JL; Rodriguez N; Martinez-Descals A; Garcia-Ruiz P; Júlio F; Januário C; Delussi M; de Tommaso M; Noguera S; Ruiz-Idiago J; Sitek EJ; Nuzzi A; Pagonabarraga J; Kulisevsky J;
    J Neurol; 2020 May; 267(5):1527-1535. PubMed ID: 32030521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington's disease.
    Bezdicek O; Majerova V; Novak M; Nikolai T; Ruzicka E; Roth J
    Appl Neuropsychol Adult; 2013; 20(1):33-40. PubMed ID: 23373682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometrics and diagnostics of the Italian version of the Alternate Verbal Fluency Battery (AVFB) in non-demented Parkinson's disease patients.
    Aiello EN; Mameli F; Ruggiero F; Zirone E; Zago S; Piacentini S; Poletti B; Reitano MR; Santangelo G; Ticozzi N; Silani V; Priori A; Ferrucci R
    Neurol Sci; 2024 Aug; 45(8):3767-3774. PubMed ID: 38467953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Montreal Cognitive Assessment (MoCA) performance in Huntington's disease patients correlates with cortical and caudate atrophy.
    Ramirez-Garcia G; Galvez V; Diaz R; Campos-Romo A; Fernandez-Ruiz J
    PeerJ; 2022; 10():e12917. PubMed ID: 35402100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of the Montreal Cognitive Assessment (MoCA) in Huntington's disease.
    Gluhm S; Goldstein J; Brown D; Van Liew C; Gilbert PE; Corey-Bloom J
    Mov Disord; 2013 Oct; 28(12):1744-7. PubMed ID: 23798501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rating scales for cognition in Huntington's disease: Critique and recommendations.
    Mestre TA; Bachoud-Lévi AC; Marinus J; Stout JC; Paulsen JS; Como P; Duff K; Sampaio C; Goetz CG; Cubo E; Stebbins GT; Martinez-Martin P;
    Mov Disord; 2018 Feb; 33(2):187-195. PubMed ID: 29278291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity and reliability of the Persian version of the Montreal Cognitive Assessment (MoCA-P) scale among subjects with Parkinson's disease.
    Badrkhahan SZ; Sikaroodi H; Sharifi F; Kouti L; Noroozian M
    Appl Neuropsychol Adult; 2020; 27(5):431-439. PubMed ID: 30821505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Chinese Version of UHDRS in Huntington's Disease: Reliability and Validity Assessment.
    Li XY; Bao YF; Xie JJ; Qian SX; Gao B; Xu M; Dong Y; Burgunder JM; Wu ZY
    J Huntingtons Dis; 2022; 11(4):407-413. PubMed ID: 36120787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease.
    Videnovic A; Bernard B; Fan W; Jaglin J; Leurgans S; Shannon KM
    Mov Disord; 2010 Feb; 25(3):401-4. PubMed ID: 20108371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The validation of the Italian version of multiple sclerosis neuropsychological screening questionnaire in Huntington's disease.
    Migliore S; D'Aurizio G; Ceccarelli C; Casella M; Curcio G; Squitieri F
    Neurol Sci; 2023 Dec; 44(12):4343-4348. PubMed ID: 37432564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the Turkish Version of the Montreal Cognitive Assessment Scale (MoCA-TR) in patients with Parkinson's disease.
    Ozdilek B; Kenangil G
    Clin Neuropsychol; 2014; 28(2):333-43. PubMed ID: 24528299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal assessment of the Unified Huntington's Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington's disease.
    Winder JY; Achterberg WP; Gardiner SL; Roos RAC
    Eur J Neurol; 2019 May; 26(5):780-785. PubMed ID: 30576046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring the functional impact of cognitive impairment in Huntington's disease.
    Horta-Barba A; Martínez-Horta S; Pérez-Pérez J; Sampedro F; Puig-Davi A; Pagonabarraga J; Kulisevsky J
    J Neurol; 2022 Jul; 269(7):3541-3549. PubMed ID: 35061089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.